Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorMetastatic Solid TumorEndometrial CancerMSI-H CancerColorectal CancerGastric CancerdMMR Cancer
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- MOMA Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT06974110
- Locations
- 🇺🇸
Investigative Site #128, Tampa, Florida, United States
🇺🇸Investigative Site #120, Detroit, Michigan, United States
🇦🇺Investigative Site #124, Woolloongabba, Queensland, Australia
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorMetastatic Solid TumorProstate CancerPancreas CancerOvarian CancerBreast CancerHomologous Recombination Deficiency
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- MOMA Therapeutics
- Target Recruit Count
- 158
- Registration Number
- NCT06545942
- Locations
- 🇺🇸
Investigative Site #108, Goodyear, Arizona, United States
🇪🇸Investigative Site #116, Barcelona, Spain
🇬🇧Investigative Site #118, Newcastle upon Tyne, United Kingdom
News
MOMA Therapeutics Initiates First-in-Human Trial of Werner Helicase Inhibitor MOMA-341 for MSI-H Solid Tumors
MOMA Therapeutics has dosed the first patient in a Phase 1 clinical trial of MOMA-341, a novel oral Werner helicase inhibitor targeting advanced or metastatic solid tumors with high microsatellite instability.